# Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

> **NCT06892223** · PHASE2 · RECRUITING · sponsor: **Istituto Clinico Humanitas** · enrollment: 42 (estimated)

## Conditions studied

- Acute Myeloid Leukaemia
- MDS (Myelodysplastic Syndrome)
- MPN (Myeloproliferative Neoplasms)

## Interventions

- **DRUG:** Monalizumab (anti-NKG2A monoclonal antibody)

## Key facts

- **NCT ID:** NCT06892223
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-03
- **Primary completion:** 2025-03-01
- **Final completion:** 2026-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06892223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06892223, "Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06892223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*